Regeneron Pharmaceuticals (REGN) Cash from Operations (2009 - 2026)

Regeneron Pharmaceuticals' Cash from Operations history runs 18 years deep, the most recent figure standing at 1078900000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 3.23% year-over-year to 1078900000.0; the TTM figure through Mar 2026 stood at 5012700000.0 (up 26.8% YoY), while the FY2025 annual figure was 4978900000.0, up 12.63% from the prior year.
• Cash from Operations was 1078900000.0 for Q1 2026 at Regeneron Pharmaceuticals, down from 1170700000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 2101700000.0 in Q1 2022 to a low of 354000000.0 in Q2 2024.
• Historically, Cash from Operations has averaged 1181600000.0 across 5 years, with a median of 1144400000.0 in 2025.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations tumbled 81.58% in 2022, then soared 223.28% in 2025.
• A 5-year view of Cash from Operations shows it stood at 1719900000.0 in 2022, then sank by 36.64% to 1089700000.0 in 2023, then gained by 15.89% to 1262800000.0 in 2024, then retreated by 7.29% to 1170700000.0 in 2025, then fell by 7.84% to 1078900000.0 in 2026.
• The last three Cash from Operations figures came in at 1078900000.0 (Q1 2026), 1170700000.0 (Q4 2025), and 1618700000.0 (Q3 2025), per Business Quant data.